1036 related articles for article (PubMed ID: 10729919)
1. Intracranial meningeal tumours in childhood: a clinicopathologic study including MIB-1 immunohistochemistry.
Demirtaş E; Erşahin Y; Yilmaz F; Mutluer S; Veral A
Pathol Res Pract; 2000; 196(3):151-8. PubMed ID: 10729919
[TBL] [Abstract][Full Text] [Related]
2. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the proliferative potential of meningiomas with MIB-1 monoclonal antibodies].
Miyagami M; Shibuya T; Miyagi A; Tsubokawa T
No To Shinkei; 1996 Jan; 48(1):39-43. PubMed ID: 8679317
[TBL] [Abstract][Full Text] [Related]
4. Correlation between histological grade, MIB-1, p53, and recurrence in 69 completely resected primary intracranial meningiomas with a 6 year mean follow-up.
Lanzafame S; Torrisi A; Barbagallo G; Emmanuele C; Alberio N; Albanese V
Pathol Res Pract; 2000; 196(7):483-8. PubMed ID: 10926326
[TBL] [Abstract][Full Text] [Related]
5. Assessment of proliferative potential of meningiomas using PCNA LI and AgNOR counts.
Sudha K; Karak AK; Sharma MC; Mathur M; Sarkar C
Indian J Pathol Microbiol; 1998 Jul; 41(3):323-30. PubMed ID: 9805855
[TBL] [Abstract][Full Text] [Related]
6. Expression of the proliferating cell nuclear antigen and clinicopathological features in intracranial meningiomas.
Kim CH; Cheong JH; Bak KH; Kim JM; Oh SJ
J Clin Neurosci; 2001 May; 8 Suppl 1():44-8. PubMed ID: 11386825
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical study of Ki-67 (MIB-1), p53 protein, p21WAF1, and p27KIP1 expression in benign, atypical, and anaplastic meningiomas.
Amatya VJ; Takeshima Y; Sugiyama K; Kurisu K; Nishisaka T; Fukuhara T; Inai K
Hum Pathol; 2001 Sep; 32(9):970-5. PubMed ID: 11567227
[TBL] [Abstract][Full Text] [Related]
8. MIB-1 staining index and peritumoral brain edema of meningiomas.
Ide M; Jimbo M; Yamamoto M; Umebara Y; Hagiwara S; Kubo O
Cancer; 1996 Jul; 78(1):133-43. PubMed ID: 8646709
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive evaluation of the malignant potential of intracranial meningiomas performed using proton magnetic resonance spectroscopy.
Shino A; Nakasu S; Matsuda M; Handa J; Morikawa S; Inubushi T
J Neurosurg; 1999 Dec; 91(6):928-34. PubMed ID: 10584837
[TBL] [Abstract][Full Text] [Related]
11. Proliferating cell nuclear antigen (PCNA) in atypical and malignant meningiomas.
Zimmer C; Gottschalk J; Cervos-Navarro J; Martin H; Beil M; Jautzke G
Pathol Res Pract; 1992 Dec; 188(8):951-8. PubMed ID: 1363764
[TBL] [Abstract][Full Text] [Related]
12. [P53 protein expression and proliferative potential in non-recurrent and recurrent meningiomas].
Miyagami M; Kanou T; Nakamura S
No To Shinkei; 1996 Aug; 48(8):719-25. PubMed ID: 8797205
[TBL] [Abstract][Full Text] [Related]
13. MIB-1 immunostaining and DNA flow cytometry in meningiomas.
Yasue M; Akasaki Y; Numoto TR; Abe S; Abe T; Takeuchi Y; Tanaka J
Noshuyo Byori; 1996 Apr; 13(1):17-20. PubMed ID: 8916122
[TBL] [Abstract][Full Text] [Related]
14. [Estrogen and progesterone receptors in meningiomas: immunohistochemical (Mib-1, p53) and clinico-morphological correlations].
Taddei GL; Caldarella A; Raspollini MR; Taddei A; Buccoliero AM
Pathologica; 2002 Feb; 94(1):10-5. PubMed ID: 11912872
[TBL] [Abstract][Full Text] [Related]
15. Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.
Torp SH; Lindboe CF; Granli US; Moen TM; Nordtømme T
Clin Neuropathol; 2001; 20(5):190-5. PubMed ID: 11594503
[TBL] [Abstract][Full Text] [Related]
16. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Ki-67/MIB-1 proliferation index in meningiomas.
Torp SH; Lindboe CF; Grønberg BH; Lydersen S; Sundstrøm S
Clin Neuropathol; 2005; 24(4):170-4. PubMed ID: 16033133
[TBL] [Abstract][Full Text] [Related]
19. Postoperative residual tumor growth of meningioma can be predicted by MIB-1 immunohistochemistry.
Nakaguchi H; Fujimaki T; Matsuno A; Matsuura R; Asai A; Suzuki I; Sasaki T; Kirino T
Cancer; 1999 May; 85(10):2249-54. PubMed ID: 10326705
[TBL] [Abstract][Full Text] [Related]
20. Hemangiopericytoma of the meninges: a clinicopathologic and immunohistochemical study.
Iwaki T; Fukui M; Takeshita I; Tsuneyoshi M; Tateishi J
Clin Neuropathol; 1988; 7(3):93-9. PubMed ID: 3060290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]